1
|
Dayanidhi DL, Watlington WK, Mantyh JB, Rupprecht G, Hsu DS. Effects and Eradication of Mycoplasma Contamination on Patient-derived Colorectal Cancer Organoid Cultures. Cancer Res Commun 2023; 3:1952-1958. [PMID: 37772998 PMCID: PMC10530407 DOI: 10.1158/2767-9764.crc-23-0109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 07/13/2023] [Accepted: 09/05/2023] [Indexed: 09/30/2023]
Abstract
Patient-derived organoids are a useful platform for identification and testing of novel precision oncology approaches. Patient-derived organoids are generated by direct culture of patient samples. However, prior to development into patient-derived organoids, these samples are often processed for clinical use, opening the potential for contamination by Mycoplasma and other microbes. While most microbes can be detected by visual inspection, Mycoplasma can go undetected and have substantial impacts on assay results. Given the increased use of patient-derived organoids, there is a growing need for a standardized protocol to detect and remove Mycoplasma from organoid models. In the current study, we report a procedure for Mycoplasma removal by passaging organoids through mice as patient-derived organoid xenografts. In vivo passage of patient-derived organoids followed by re-establishment was 100% effective at decontaminating colorectal patient-derived organoids (n = 9), based on testing with the Sigma LookOut Mycoplasma PCR Detection Kit. This process can serve as a method to re-establish contaminated patient-derived organoids, which represent precious models to study patient-specific genomic features and treatment responses. SIGNIFICANCE Organoids are valuable models of cancer. Mycoplasma contamination can alter organoid drug sensitivity, so there is a need for a standardized protocol to detect and remove Mycoplasma from organoids. We report a simple procedure for removing Mycoplasma from organoids via in vivo passaging through mice followed by re-establishment of organoids.
Collapse
Affiliation(s)
- Divya L. Dayanidhi
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
- Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - Wylie K. Watlington
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
- Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - John B. Mantyh
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
- Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - Gabrielle Rupprecht
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
- Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - David S. Hsu
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
- Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| |
Collapse
|
2
|
Dayanidhi DL, Somarelli JA, Mantyh JB, Rupprecht G, Roghani RS, Vincoff S, Shin I, Zhao Y, Kim SY, McCall S, Hong J, Hsu DS. Corrigendum: Psymberin, a marine-derived natural product, induces cancer cell growth arrest and protein translation inhibition. Front Med (Lausanne) 2023; 10:1193745. [PMID: 37324143 PMCID: PMC10265623 DOI: 10.3389/fmed.2023.1193745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Accepted: 05/18/2023] [Indexed: 06/17/2023] Open
Abstract
[This corrects the article DOI: 10.3389/fmed.2022.999004.].
Collapse
Affiliation(s)
- Divya L. Dayanidhi
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Jason A. Somarelli
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
| | - John B. Mantyh
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Gabrielle Rupprecht
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Roham Salman Roghani
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Sophia Vincoff
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
| | - Iljin Shin
- Department of Chemistry, Duke University, Durham, NC, United States
| | - Yiquan Zhao
- Department of Chemistry, Duke University, Durham, NC, United States
| | - So Young Kim
- Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, United States
| | - Shannon McCall
- Department of Pathology, Duke University, Durham, NC, United States
| | - Jiyong Hong
- Department of Chemistry, Duke University, Durham, NC, United States
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, United States
| | - David S. Hsu
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| |
Collapse
|
3
|
Dayanidhi DL, Somarelli JA, Mantyh JB, Rupprecht G, Roghani RS, Vincoff S, Shin I, Zhao Y, Kim SY, McCall S, Hong J, Hsu DS. Psymberin, a marine-derived natural product, induces cancer cell growth arrest and protein translation inhibition. Front Med (Lausanne) 2022; 9:999004. [PMID: 36743670 PMCID: PMC9894252 DOI: 10.3389/fmed.2022.999004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 10/18/2022] [Indexed: 01/20/2023] Open
Abstract
Colorectal cancer (CRC) is the third most prevalent form of cancer in the United States and results in over 50,000 deaths per year. Treatments for metastatic CRC are limited, and therefore there is an unmet clinical need for more effective therapies. In our prior work, we coupled high-throughput chemical screens with patient-derived models of cancer to identify new potential therapeutic targets for CRC. However, this pipeline is limited by (1) the use of cell lines that do not appropriately recapitulate the tumor microenvironment, and (2) the use of patient-derived xenografts (PDXs), which are time-consuming and costly for validation of drug efficacy. To overcome these limitations, we have turned to patient-derived organoids. Organoids are increasingly being accepted as a "standard" preclinical model that recapitulates tumor microenvironment cross-talk in a rapid, cost-effective platform. In the present work, we employed a library of natural products, intermediates, and drug-like compounds for which full synthesis has been demonstrated. Using this compound library, we performed a high-throughput screen on multiple low-passage cancer cell lines to identify potential treatments. The top candidate, psymberin, was further validated, with a focus on CRC cell lines and organoids. Mechanistic and genomics analyses pinpointed protein translation inhibition as a mechanism of action of psymberin. These findings suggest the potential of psymberin as a novel therapy for the treatment of CRC.
Collapse
Affiliation(s)
- Divya L. Dayanidhi
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Jason A. Somarelli
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
| | - John B. Mantyh
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Gabrielle Rupprecht
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Roham Salman Roghani
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| | - Sophia Vincoff
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
| | - Iljin Shin
- Department of Chemistry, Duke University, Durham, NC, United States
| | - Yiquan Zhao
- Department of Chemistry, Duke University, Durham, NC, United States
| | - So Young Kim
- Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, United States
| | - Shannon McCall
- Department of Pathology, Duke University, Durham, NC, United States
| | - Jiyong Hong
- Department of Chemistry, Duke University, Durham, NC, United States
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, United States
| | - David S. Hsu
- Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, United States
- Center for Genomics and Computational Biology, Duke University, Durham, NC, United States
| |
Collapse
|
4
|
Somarelli JA, Roghani RS, Moghaddam AS, Thomas BC, Rupprecht G, Ware KE, Altunel E, Mantyh JB, Kim SY, McCall SJ, Shen X, Mantyh CR, Hsu DS. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Mol Cancer Ther 2020; 19:2516-2527. [PMID: 33158998 DOI: 10.1158/1535-7163.mct-20-0454] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 08/15/2020] [Accepted: 09/28/2020] [Indexed: 12/26/2022]
Abstract
Colorectal cancer is the third most common cancer in the United States and responsible for over 50,000 deaths each year. Therapeutic options for advanced colorectal cancer are limited, and there remains an unmet clinical need to identify new treatments for this deadly disease. To address this need, we developed a precision medicine pipeline that integrates high-throughput chemical screens with matched patient-derived cell lines and patient-derived xenografts (PDX) to identify new treatments for colorectal cancer. High-throughput screens of 2,100 compounds were performed across six low-passage, patient-derived colorectal cancer cell lines. These screens identified the CDK inhibitor drug class among the most effective cytotoxic compounds across six colorectal cancer lines. Among this class, combined targeting of CDK1, 2, and 9 was the most effective, with IC50s ranging from 110 nmol/L to 1.2 μmol/L. Knockdown of CDK9 in the presence of a CDK2 inhibitor (CVT-313) showed that CDK9 knockdown acted synergistically with CDK2 inhibition. Mechanistically, dual CDK2/9 inhibition induced significant G2-M arrest and anaphase catastrophe. Combined CDK2/9 inhibition in vivo synergistically reduced PDX tumor growth. Our precision medicine pipeline provides a robust screening and validation platform to identify promising new cancer therapies. Application of this platform to colorectal cancer pinpointed CDK2/9 dual inhibition as a novel combinatorial therapy to treat colorectal cancer.
Collapse
Affiliation(s)
- Jason A Somarelli
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
| | - Roham Salman Roghani
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.,Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - Ali Sanjari Moghaddam
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.,Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - Beatrice C Thomas
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
| | - Gabrielle Rupprecht
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.,Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - Kathryn E Ware
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
| | - Erdem Altunel
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.,Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - John B Mantyh
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.,Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| | - So Young Kim
- Duke Functional Genomics Core, Duke University, Durham, North Carolina
| | - Shannon J McCall
- Department of Pathology, Duke University, Durham, North Carolina
| | - Xiling Shen
- Center for Genomics and Computational Biology, Duke University, Durham, North Carolina.,Department of Biomedical Engineering, Duke University, Durham, North Carolina
| | | | - David S Hsu
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina. .,Center for Genomics and Computational Biology, Duke University, Durham, North Carolina
| |
Collapse
|